Partial
Mostly Aligned
Patient Risk:
Low
Summary
Several core label-consistent claims are present (active ingredient, SGLT2 class mechanism, and major indication-risk statements). However, multiple claims are not supported by the provided FDA label text, including comparator drugs (Jardiance/Farxiga/Steglatro), external patent/generic-market assertions, and specific “common side effects” and ketoacidosis definition/etiology statements.
Category Scores
Accurate Statements
Invokana is a brand-name medication containing the active ingredient canagliflozin.
11 DESCRIPTION
Invokana is prescribed to manage type 2 diabetes by improving blood sugar control.
1 INDICATIONS AND USAGE
Invokana is used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
1 INDICATIONS AND USAGE
Invokana belongs to the class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors.
11 DESCRIPTION
SGLT2 inhibitors work by preventing the kidneys from reabsorbing sugar back into the blood.
11 DESCRIPTION (SGLT2 transporter responsible for reabsorbing filtered glucose)
SGLT2 inhibitors cause excess sugar to be removed from the body through urine.
7 DRUG INTERACTIONS (Positive urine glucose test; increased urinary glucose excretion)
Invokana can cause ketoacidosis.
6 ADVERSE REACTIONS (Diabetic Ketoacidosis... [Warnings and Precautions reference])
Invokana carries a risk of lower limb amputations.
6 ADVERSE REACTIONS (Lower Limb Amputation)
Invokana may reduce the risk of major cardiovascular events such as heart attack, stroke, or cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease.
1 INDICATIONS AND USAGE (reduction of major adverse cardiovascular events: cardiovascular death, nonfatal MI, nonfatal stroke in adults with established CVD)
Invokana is prescribed to reduce the risk of end-stage kidney disease in patients with type 2 diabetes and diabetic nephropathy.
1 INDICATIONS AND USAGE (reduce risk of end-stage kidney disease)
Invokana is prescribed to reduce the risk of cardiovascular death in patients with type 2 diabetes and diabetic nephropathy.
1 INDICATIONS AND USAGE (reduce risk of CV death)
Invokana is prescribed to reduce the risk of hospitalization due to heart failure in patients with type 2 diabetes and diabetic nephropathy.
1 INDICATIONS AND USAGE (hospitalization for heart failure)
Unsupported Statements
As of December 2023, there is no generic version of Invokana available in the United States.
Not supported by the provided FDA label sections (external market/generic-status statement not present).
Jardiance is an SGLT2 inhibitor (empagliflozin).
Provided FDA label excerpt is for Invokana only; no information about Jardiance in the supplied label sections.
Farxiga is an SGLT2 inhibitor (dapagliflozin).
Provided FDA label excerpt is for Invokana only; no information about Farxiga in the supplied label sections.
Steglatro is an SGLT2 inhibitor (ertugliflozin).
Provided FDA label excerpt is for Invokana only; no information about Steglatro in the supplied label sections.
Jardiance, Farxiga, and Steglatro are prescribed for type 2 diabetes management.
No such cross-product prescribing claims are present in the provided Invokana label sections.
Jardiance, Farxiga, and Steglatro may have similar benefits and risks to Invokana.
The provided Invokana label does not provide comparative benefits/risks across other products.
Common side effects of Invokana include yeast infections of the vagina.
The provided label excerpt lists genitourinary infections as important adverse reactions, but does not provide the claim framed as “common side effects” nor the specific “yeast infections of the vagina” side-effect frequency wording.
Common side effects of Invokana include urinary tract infections.
The provided label excerpt references genitourinary infections including urosepsis/pyelonephritis, but does not provide the claim framed as “common side effects” or a specific “urinary tract infections” common-side-effect statement.
Ketoacidosis is described as a serious condition where the body produces high levels of blood acids called ketones.
The provided label excerpt references ketoacidosis as an adverse reaction but does not include this definition/description.
The exact cause of Invokana-related lower limb amputations is not fully understood.
No causation/knowledge statement about lower limb amputations appears in the provided label excerpt.
Information regarding Invokana's patent status, including challenges or expiration dates, is publicly available.
Not supported by the provided FDA label sections (external patent-status statement not present).
Resources like DrugPatentWatch.com track Invokana patent details.
External resource claim not supported by the provided FDA label sections.
Contradictions
Low
AI Statement
Invokana is prescribed to reduce the risk of worsening of kidney disease in patients with type 2 diabetes and diabetic nephropathy.
Label Reference
1 INDICATIONS AND USAGE
Important Omissions
No dosage and administration details were provided in the AI claims, despite being part of the requested label alignment dimensions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Unsupported external and comparator statements do not directly change Invokana-specific safety instructions. However, “common side effects” claims and an imprecise kidney-outcome wording are not substantiated by the provided label excerpts; these could mislead interpretation of frequency or endpoint framing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Multiple statements are not supported by the provided Invokana FDA label excerpt, including comparator-brand/class details, “common side effects” frequency framing, ketoacidosis definition, and external patent/generic assertions.
Suggested Improvement
Limit claims to the provided label-supported Invokana content (indications and listed important adverse reactions) and remove/avoid external market/patent and other-brand comparative assertions unless corresponding FDA-label sections are provided.